JERSEY CITY, N.J., Oct. 3, 2025 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced four poster presentations on investigational ND0612 in Parkinson's disease (PD) will be shared at the 2025 International Congress of Parkinson's Disease and Movement Disorders®, being held October 5-9 in Honolulu, HI. ND0612 is being evaluated as a 24-hour, continuous, subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD).

"We look forward to hearing from leading experts in the field at the meeting and discussing new data on ND0612," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. "We continue to refine our understanding of the potential of ND0612 and are committed to collaborating with the greater scientific community to drive forward inn

See Full Page